The Sirt1/Nrf2 Pathway is a Key Factor for Drug Therapy in Chemotherapy-induced Cardiotoxicity: a Mini-Review

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Sep 11

PMID 39259412

Authors

Suleiman Ibrahim Shelash Mohammad

Asokan Vasudevan

Felix Oghenemaro Enwa

Jaya Bansal

Mamata Chahar

Mamdouh Eldesoqui

Muhammad Ikram Ullah

Zhanna R Gardanova

Hanen Mahmod Hulail

Ahmed Hussein Zwamel

Affiliations

Soon will be listed here.

Abstract

The likelihood of survival for cancer patients has greatly improved due to chemotherapy medicines. However, these antitumor agents might also have unfavorable effects on the cardiovascular system, which could result in sudden or gradual cardiac failure. The production of free radicals that result in oxidative stress appears to be the key mechanism by which chemotherapy-induced cardiotoxicity (CIC) happens. Reports suggest that the Sirtuin-1 (Sirt1)/Nuclear factor E2-associated factor 2 (Nrf2) signaling pathway has been considered an alternative path for counteracting cardiotoxicity by suppressing oxidative stress, inflammation, and apoptosis. This review concludes recent knowledge about CIC with a special focus on the anti-oxidative regulation properties of the Sirt1/Nrf2 pathway.

References

Bandyopadhyay D, Chattopadhyay A, Ghosh G, Datta A . Oxidative stress-induced ischemic heart disease: protection by antioxidants. Curr Med Chem. 2004; 11(3):369-87. DOI: 10.2174/0929867043456016. View

Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D . Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016; 66(4):309-25. DOI: 10.3322/caac.21341. View

de Moor J, Mariotto A, Parry C, Alfano C, Padgett L, Kent E . Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):561-70. PMC: 3654837. DOI: 10.1158/1055-9965.EPI-12-1356. View

Falzone L, Salomone S, Libra M . Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018; 9:1300. PMC: 6243123. DOI: 10.3389/fphar.2018.01300. View

DeVita Jr V, Chu E . A history of cancer chemotherapy. Cancer Res. 2008; 68(21):8643-53. DOI: 10.1158/0008-5472.CAN-07-6611. View

Li H, Fan H, Lu K, Zhu Q, Wu J . Purification of Extracellular Protease from QB7and Its Ability in Generating Antioxidant and Anti-inflammatory Peptides from Meat Proteins. Nutrients. 2023; 15(1). PMC: 9824131. DOI: 10.3390/nu15010065. View

Bhagat A, Kleinerman E . Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020; 1257:181-192. DOI: 10.1007/978-3-030-43032-0_15. View

Liu P, Li J, Liu M, Zhang M, Xue Y, Zhang Y . Hesperetin modulates the Sirt1/Nrf2 signaling pathway in counteracting myocardial ischemia through suppression of oxidative stress, inflammation, and apoptosis. Biomed Pharmacother. 2021; 139:111552. DOI: 10.1016/j.biopha.2021.111552. View

Suter T, Ewer M . Cancer drugs and the heart: importance and management. Eur Heart J. 2012; 34(15):1102-11. DOI: 10.1093/eurheartj/ehs181. View

10.

Ewer M, Vooletich M, Durand J, Woods M, Davis J, Valero V . Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005; 23(31):7820-6. DOI: 10.1200/JCO.2005.13.300. View

11.

Gianni L, Herman E, Lipshultz S, Minotti G, Sarvazyan N, Sawyer D . Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008; 26(22):3777-84. PMC: 3018290. DOI: 10.1200/JCO.2007.14.9401. View

12.

Smith L, Cornelius V, Plummer C, Levitt G, Verrill M, Canney P . Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010; 10:337. PMC: 2907344. DOI: 10.1186/1471-2407-10-337. View

13.

Cardinale D, Sandri M, Martinoni A, Borghini E, Civelli M, Lamantia G . Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002; 13(5):710-5. DOI: 10.1093/annonc/mdf170. View

14.

Mann D, Bristow M . Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111(21):2837-49. DOI: 10.1161/CIRCULATIONAHA.104.500546. View

15.

Soignet S, Frankel S, Douer D, Tallman M, Kantarjian H, Calleja E . United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19(18):3852-60. DOI: 10.1200/JCO.2001.19.18.3852. View

16.

Subbiah V, Hu M, Wirth L, Schuler M, Mansfield A, Curigliano G . Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021; 9(8):491-501. DOI: 10.1016/S2213-8587(21)00120-0. View

17.

Kantarjian H, Hochhaus A, Saglio G, de Souza C, Flinn I, Stenke L . Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12(9):841-51. DOI: 10.1016/S1470-2045(11)70201-7. View

18.

Moore R, Adel N, Riedel E, Bhutani M, Feldman D, Tabbara N . High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011; 29(25):3466-73. PMC: 6815979. DOI: 10.1200/JCO.2011.35.5669. View

19.

Nalluri S, Chu D, Keresztes R, Zhu X, Wu S . Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008; 300(19):2277-85. DOI: 10.1001/jama.2008.656. View

20.

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-76. DOI: 10.1056/NEJMoa072113. View